KIT V559_V560DEL

CI-VAR-00004550Explore in graph →NP_000213.1:p.Val559_Val560delNM_000222.2:c.1676_1681delTTGTTGCIViC 967

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastrointestinal Stromal Tumor3
KIT V559_V560DEL	Imatinib	Predictive	D	Supports Sensitivity Response	—	submitted	EID2452 Molecular models predict that deletion of a portion of the juxtamembrane domain relieves steric hindrance and results in higher binding affinity for imatinib. PMID 21364689 · Pierotti et al., 2011 · Open in CIViC	civic
KIT V559_V560DEL	Sunitinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4105 In a retrospective study of 123 metastatic or advanced gastrointestinal stromal tumor patients with KIT exon 11 mutations, patients with KIT exon 11 mutations were reported to be responsive to sunitin… (full text at CIViC) PMID 26416414 · Vincenzi et al., 2016 · Open in CIViC	civic
KIT V559_V560DEL

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.